Multi-Center Comparison of Response to a Single Tablet of Sumatriptan 85 mg and Naproxen 500 mg vs Usual Therapy Treating Multiple Migraine Attacks as Measured by the Completeness of Response Survey

• Published in: Headache Vol. 51; no. 6; pp. 961 - 970
• Main Authors: Cady, Roger, Banks, Jim, Nett, Robert B., Goldstein, Jerome, Bennett, Nathan, Turner, Ira M., Ruoff, Gary E., Landy, Stephen H., Farmer, Kathleen, Juhász, Márta, Tarrasch, Jeanne, Runken, M. Chris
• Format: Journal Article
• Language: English
• Published: Malden, USA Blackwell Publishing Inc 01.06.2011; Wiley-Blackwell; Wiley Subscription Services, Inc
• Subjects: Acute Disease; acute migraine; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Biological and medical sciences; Cardiovascular system; Drug Therapy, Combination; Female; Headache Impact Test; Headaches; Health Surveys; Humans; Male; Medical sciences; Middle Aged; Migraine; migraine symptom resolution; Migraine with Aura - drug therapy; Migraine with Aura - physiopathology; Migraine without Aura - drug therapy; Migraine without Aura - physiopathology; Naproxen - administration & dosage; Neurology; patient satisfaction; Pharmacology. Drug treatments; Recovery of Function; Revised Patient Perception of Migraine Questionnaire; Serotonin 5-HT1 Receptor Agonists - administration & dosage; SumaRT/Nap; Sumatriptan - administration & dosage; Vascular diseases and vascular malformations of the nervous system; Vasodilator agents. Cerebral vasodilators; Young Adult; Prostaglandin-endoperoxide synthase; Headache; Agonist; Sumatriptan; Cardiovascular disease; 5-HT1 Serotonine receptor; Headache Impact Test; Serotonin agonist; Vascular disease; SumaRT/Nap; acute migraine; Pain; Naproxen; Triptan derivatives; Arylpropionic acid derivatives; Tablet; Neurological disorder; Cerebrovascular disease; migraine symptom resolution; Human; Nervous system diseases; Revised Patient Perception of Migraine Questionnaire; Enzyme; Antimigrainous agent; Migraine; Enzyme inhibitor; Cerebral disorder; Non steroidal antiinflammatory agent; patient satisfaction; Analgesic; Treatment; Central nervous system disease; Antipyretic; Perception; Oxidoreductases; Comparative study
• ISSN: 0017-8748; 1526-4610; 1526-4610
• DOI: 10.1111/j.1526-4610.2011.01912.x

(Headache 2011;51:961‐970) Objective.— To investigate a broad definition of migraine resolution that extends beyond specific migraine‐associated diagnostic symptoms as measured by the Completeness of Response Survey. Methods.— Conducted at 8 sites, 135 subjects treated migraines with SumaRT/Nap over 2 months. To measure subjects' experiences with SumaRT/Nap compared to their usual migraine medication, the Headache Impact Test, Revised Patient Perception of Migraine Questionnaire, and Completeness of Response Survey were administered at baseline and at 2 months. Results.— The effects of the study medicine compared to the subjects' usual migraine medicine reached statistical significance in decreasing headache severity, lessening of associated symptoms, and attaining complete relief with a single dose (60.04% of attacks resolved at 2 hours post‐treatment). Conclusion.— Compared to a subject's usual treatment, SumaRT/Nap used early and consistently for treatment of acute migraine offers important clinical improvements, including lessening of associated symptoms beyond International Headache Society criteria.